AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...
Tozorakimab, an investigational monoclonal antibody targeting the IL-33 pathway, significantly reduced moderate-to-severe ...
The trio of positive studies means that AZ is in pole position to bring an anti-IL-33 drug to market for COPD, after some ...
AstraZeneca has reported positive high-level results from the phase 3 MIRANDA trial of tozorakimab, showing a statistically ...
Clinical Trials Arena on MSN
AstraZeneca’s COPD drug gains third Phase III win
Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.
Tozorakimab met its primary endpoint in the MIRANDA trial, demonstrating the potential of IL-33 inhibition to reduce exacerbations and improve outcomes for a broad population of COPD patients. Topline ...
The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled out mixed results from a pair of studies testing the compound vs. placebo on ...
Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...
Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results